Imugene Ltd: Imugene Webinar - Azer-cel Trial Update
Imugene Ltd: Three Complete Responses in Azer-Cel Phase 1b Trial
Imugene Ltd: Imugene ESG Report 2024
Imugene Ltd: Corporate Governance Statement 2024 and Appendix 4G
Imugene Ltd: Release of Shares from Voluntary Escrow
Imugene Ltd: Quarterly Activities/Appendix 4C Cash Flow Report
Imugene Ltd: First patient dosed in Phase 1 bile tract cancer trial
Imugene Ltd: Change of Director's Interest Notice x6
Imugene Ltd: Imugene onCARlytics Doses First Patient in IV Combination
Imugene Ltd: Quarterly Activities/Appendix 4C Cash Flow Report
Imugene Ltd: Change of Director's Interest Notice - PH
Imugene Ltd: Imugene & Kincell Bio Strategic Partnership Investor Webinar
Imugene Ltd: Imugene and Kincell Bio Announce Strategic Partnership
Imugene Ltd: Bile Tract Cancer Study Opens after MAST High Dose Clearance
Imugene Ltd: VAXINIA and HER-Vaxx featured at the AACR Annual Meeting
Imugene Ltd: Oncolytic Virotherapy CF33 Patent Granted in China
Imugene Ltd: Imugene to present at 2024 Cholangiocarcinoma Conference
Imugene Ltd: Phase 1 onCARlytics Trial Advances to Combination Arm
Imugene Ltd: Phase 1 onCARlytics Trial Doses First Intravenous Patient
Imugene Ltd: Change of Director's Interest Notice - PH
No Data